Write in a clean editor, then format for The Journal of Liquid Biopsy in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
The Journal of Liquid Biopsy is a peer-reviewed journal published by Elsevier, covering Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Cancer Cells and Metastasis.
| Publisher | Elsevier |
|---|---|
| Reference style | Numbered (Elsevier) Numbered — [1], [2] in the text [1] A. Smith, B. Jones, C. Lee, A representative article title, The Journal of Liquid Biopsy 12 (2023) 45–58.
Formats any DOI in The Journal of Liquid Biopsy style. No sign-up. |
| Publishes research in | Cancer Genomics and Diagnostics Lung Cancer Treatments and Mutations Cancer Cells and Metastasis Extracellular vesicles in disease Molecular Biology Techniques and Applications |
| ISSN | 2950-1954 |
| Citation impact (2-yr) | 2.72 |
| h-index | 17 |
| i10-index | 35 |
| Total citations | 1,115 |
| Open access | Yes |
| Top institutions publishing here | Centro de Investigación Biomédica en Red de Cáncer |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Extracellular vesicles (EVs) are nanovesicles released from different cell types from biofluids such as blood, urine, and cerebrospinal fluid. They vary in size and biomarkers, and their biogenesis pathways allow them to be divided into three major types: exosomes, micro-vesicles, and apoptotic bodies. EVs have been studied in the context of diagnosis and therapeutic intervention…
As precision oncology has become a major part of the treatment landscape in oncology, liquid biopsies have developed as a particularly powerful tool as it surmounts several limitations of traditional tissue biopsies. These biopsies involve most commonly the isolation of circulating extracellular nucleic acids, including cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA), as well…
Liquid biopsies have emerged as groundbreaking tools for minimally invasive monitoring of cancer, encompassing the analysis of Cell-Free DNA (cfDNA), circulating tumor DNA (ctDNA) and exosomes. This paradigm shift offers an emerging approach for understanding tumor dynamics, treatment responses, and disease progression. Leveraging advancements in molecular biology and technology, liquid biopsies enable clinicians to gain…
Liquid biopsy offers a minimally invasive method for detecting and monitoring cancer, with key biomarkers including circulating tumor cells (CTCs), cell-free DNA (cfDNA), and extracellular vesicles (EVs). Among these, CTCs provide dynamic insights into tumor heterogeneity, metastatic potential, and therapeutic resistance through molecular profiling and single-cell analysis. This review examines recent advancements in technologies such…
Circulating tumor DNA (ctDNA) testing has transformed precision oncology by enabling the non-invasive detection of actionable mutations. To facilitate broader clinical adoption and improve testing accuracy, standardized quality criteria must be clearly defined and universally implemented. The International Society of Liquid Biopsy (ISLB) established the Quality Control and Accreditation Committee to develop consensus-based minimal standards…
